Australia · Delayed Price · Currency is AUD Cyclopharm Earnings Call Transcripts
Fiscal Year 2026
-
Record half-year revenue up 14% to AUD 17.5 million, driven by 74% U.S. growth and margin expansion. New international guidelines name Technegas as preferred agent, supporting accelerated U.S. adoption and expansion into broader indications.
Fiscal Year 2025
-
Record revenue growth of 26% year-over-year was driven by U.S. expansion, doubling sales and installations, and strong third-party distribution. Guidance remains intact with a robust sales pipeline and significant cash inflow expected from a non-core asset sale.
-
Major US contracts and FDA approval have driven record revenue and strong US market momentum, with Technegas now installed in 24 US sites and expanding globally. Recurring consumable sales and clinical evidence support robust growth, while AI integration and beyond PE applications offer further upside.